Healthcare & Life Sciences

Avidity Biosciences

aliveseries-c-plus
series-c-plus
Stage
4
Investors

About

Avidity Biosciences develops targeted RNA therapeutics using its proprietary Antibody Oligonucleotide Conjugates (AOC) platform to treat rare muscle diseases by targeting the underlying genetic causes.

Explore Avidity Biosciences's full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.